This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GA-GCSF

Shire Pharmaceuticals Group PLC

Drug Names(s): Gene-Activated Granulocyte Colony Stimulating Factor

Description: Gene-Activated GCSF stimulates the production of the infection fighting white blood cells called neutrophils. Gene-activation technology is a method of producing the protein. Instead of inserting human genes into bacteria, yeast, or mammalian cells, gene-activation involves human cells, utlizing DNA sequences to allow the gene for the protein to be expressed (the genes are normally turned off in most cells).

Deal Structure: GA-GCSF was originally developed by Transkaryotic Therapies under a collaboration agreement with Aventis. In November 2000, TKT and Aventis terminated their collaboration relating to GA-GCSF, and TKT reacquired the rights to GA-GCSF.

In July 2005, Shire acquired Transkaryotic Therapies (TKT).

Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

In October 2014, AbbVie and Shire have agreed to terminate their proposed merger following the decision by AbbVies Board to withdraw support for the proposed transaction. The Companys decision was based upon its assessment of the September 22, 2014 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions.


GA-GCSF News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug